Michael F Armstrong, Brian J Burkett, Thomas J O'Byrne, Harrison C Gottlich, Linda X Yin, Kendall K Tasche, Daniel L Price, Eric J Moore, David M Routman, Mauricio Gamez, Scott C Lester, Michelle A Neben-Wittich, Daniel J Ma, Katharine A Price, Val J Lowe, Kathryn M Van Abel
{"title":"不对称口咽部正电子发射断层扫描意外摄取患者中的癌症","authors":"Michael F Armstrong, Brian J Burkett, Thomas J O'Byrne, Harrison C Gottlich, Linda X Yin, Kendall K Tasche, Daniel L Price, Eric J Moore, David M Routman, Mauricio Gamez, Scott C Lester, Michelle A Neben-Wittich, Daniel J Ma, Katharine A Price, Val J Lowe, Kathryn M Van Abel","doi":"10.1001/jamaoto.2024.2556","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>Asymmetric oropharynx uptake on positron emission tomography (PET)/computed tomography (CT) is a common incidental finding and often prompts otolaryngology referral to rule out malignancy; however, the true risk of malignancy based on this finding is unknown.</p><p><strong>Objective: </strong>To identify the incidence of oropharynx cancer in patients with incidental asymmetric oropharynx PET uptake.</p><p><strong>Design, setting, and participants: </strong>In this retrospective cohort study, patients 18 years and older undergoing PET/CT scans at Mayo Clinic between January 2001 and December 2018 were included. Patients with a history or pretest suspicion of oropharynx cancer were excluded. Data were analyzed from March 2021 to December 2023.</p><p><strong>Exposure: </strong>Blinded radiologic review of imaging studies, including measurement of maximum standardized uptake values (SUVmax) of the ipsilateral side of concern and contralateral side. Retrospective medical record review for associated clinical data.</p><p><strong>Main outcomes and measures: </strong>The primary study outcome was the incidence of oropharynx cancer diagnosis in patients with asymmetric oropharynx PET uptake. The primary outcome was formulated before data collection.</p><p><strong>Results: </strong>Of the 1854 patients identified with asymmetric oropharynx PET uptake, 327 (17.6%) met inclusion criteria. Of these, 173 (52.9%) were male, and the median (range) age was 65.0 (24.8-90.7) years. The mean (SD) follow-up interval was 52.1 (43.4) months. A total of 18 of 327 patients (5.5%) were newly diagnosed with oropharynx cancer. The most common diagnosis was squamous cell carcinoma (n = 9), followed by lymphoma (n = 8), and sarcoma (n = 1). Patients with an incidental diagnosis of oropharynx cancer had higher mean (SD) ipsilateral SUVmax (8.7 [3.7] vs 5.3 [1.9]) and SUVmax ratio (3.0 [1.6] vs 1.6 [0.6]) compared with patients with normal examination findings. SUVmax ratio and difference were found to be good discriminators of oropharynx cancer, with areas under the receiver operating characteristic curve of 86.3% (95% CI, 76.4-94.6) and 85.8% (95% CI, 74.8-94.6), respectively. Patients with a new diagnosis of oropharynx cancer were more likely to have a corresponding CT abnormality than those with normal examination findings (6 of 18 [33%] vs 24 of 295 [8.1%]). Patients with concerning lesions on oropharynx palpation by an otolaryngology health care professional were significantly more likely to be diagnosed with oropharynx cancer compared with patients with normal examination findings (odds ratio, 28.4; 95% CI, 6.6-145.8).</p><p><strong>Conclusions and relevance: </strong>In this cohort study, while incidental asymmetric oropharynx PET uptake was common, a new diagnosis of oropharynx cancer was not and potentially results in a large volume of unnecessary referrals and work-up. Using SUVmax ratio, SUVmax difference, and CT correlation may increase the benefit of referral. Patients with a palpable oropharynx lesion and asymmetric oropharynx PET uptake should undergo confirmatory biopsy.</p>","PeriodicalId":14632,"journal":{"name":"JAMA otolaryngology-- head & neck surgery","volume":" ","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11362974/pdf/","citationCount":"0","resultStr":"{\"title\":\"Cancer in Patients With Incidental Asymmetric Oropharynx Positron Emission Tomography Uptake.\",\"authors\":\"Michael F Armstrong, Brian J Burkett, Thomas J O'Byrne, Harrison C Gottlich, Linda X Yin, Kendall K Tasche, Daniel L Price, Eric J Moore, David M Routman, Mauricio Gamez, Scott C Lester, Michelle A Neben-Wittich, Daniel J Ma, Katharine A Price, Val J Lowe, Kathryn M Van Abel\",\"doi\":\"10.1001/jamaoto.2024.2556\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Importance: </strong>Asymmetric oropharynx uptake on positron emission tomography (PET)/computed tomography (CT) is a common incidental finding and often prompts otolaryngology referral to rule out malignancy; however, the true risk of malignancy based on this finding is unknown.</p><p><strong>Objective: </strong>To identify the incidence of oropharynx cancer in patients with incidental asymmetric oropharynx PET uptake.</p><p><strong>Design, setting, and participants: </strong>In this retrospective cohort study, patients 18 years and older undergoing PET/CT scans at Mayo Clinic between January 2001 and December 2018 were included. Patients with a history or pretest suspicion of oropharynx cancer were excluded. Data were analyzed from March 2021 to December 2023.</p><p><strong>Exposure: </strong>Blinded radiologic review of imaging studies, including measurement of maximum standardized uptake values (SUVmax) of the ipsilateral side of concern and contralateral side. Retrospective medical record review for associated clinical data.</p><p><strong>Main outcomes and measures: </strong>The primary study outcome was the incidence of oropharynx cancer diagnosis in patients with asymmetric oropharynx PET uptake. The primary outcome was formulated before data collection.</p><p><strong>Results: </strong>Of the 1854 patients identified with asymmetric oropharynx PET uptake, 327 (17.6%) met inclusion criteria. Of these, 173 (52.9%) were male, and the median (range) age was 65.0 (24.8-90.7) years. The mean (SD) follow-up interval was 52.1 (43.4) months. A total of 18 of 327 patients (5.5%) were newly diagnosed with oropharynx cancer. The most common diagnosis was squamous cell carcinoma (n = 9), followed by lymphoma (n = 8), and sarcoma (n = 1). Patients with an incidental diagnosis of oropharynx cancer had higher mean (SD) ipsilateral SUVmax (8.7 [3.7] vs 5.3 [1.9]) and SUVmax ratio (3.0 [1.6] vs 1.6 [0.6]) compared with patients with normal examination findings. SUVmax ratio and difference were found to be good discriminators of oropharynx cancer, with areas under the receiver operating characteristic curve of 86.3% (95% CI, 76.4-94.6) and 85.8% (95% CI, 74.8-94.6), respectively. Patients with a new diagnosis of oropharynx cancer were more likely to have a corresponding CT abnormality than those with normal examination findings (6 of 18 [33%] vs 24 of 295 [8.1%]). Patients with concerning lesions on oropharynx palpation by an otolaryngology health care professional were significantly more likely to be diagnosed with oropharynx cancer compared with patients with normal examination findings (odds ratio, 28.4; 95% CI, 6.6-145.8).</p><p><strong>Conclusions and relevance: </strong>In this cohort study, while incidental asymmetric oropharynx PET uptake was common, a new diagnosis of oropharynx cancer was not and potentially results in a large volume of unnecessary referrals and work-up. Using SUVmax ratio, SUVmax difference, and CT correlation may increase the benefit of referral. Patients with a palpable oropharynx lesion and asymmetric oropharynx PET uptake should undergo confirmatory biopsy.</p>\",\"PeriodicalId\":14632,\"journal\":{\"name\":\"JAMA otolaryngology-- head & neck surgery\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":6.0000,\"publicationDate\":\"2024-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11362974/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAMA otolaryngology-- head & neck surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1001/jamaoto.2024.2556\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA otolaryngology-- head & neck surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamaoto.2024.2556","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
重要性:正电子发射计算机断层扫描(PET)/计算机断层扫描(CT)的非对称口咽摄取是一种常见的偶然发现,通常会促使耳鼻喉科转诊以排除恶性肿瘤;然而,基于这一发现的真正恶性肿瘤风险尚不清楚:目的:确定意外非对称口咽部 PET 摄取患者的口咽癌发病率:在这项回顾性队列研究中,纳入了 2001 年 1 月至 2018 年 12 月期间在梅奥诊所接受 PET/CT 扫描的 18 岁及以上患者。排除了有口咽癌病史或检测前怀疑口咽癌的患者。数据分析时间为2021年3月至2023年12月。暴露:对影像学研究进行盲法放射学审查,包括测量同侧和对侧最大标准化摄取值(SUVmax)。对相关临床数据进行回顾性病历审查:主要研究结果是口咽 PET 摄取不对称患者的口咽癌诊断率。主要结果在数据收集前已制定:在 1854 名口腔咽部 PET 摄取不对称的患者中,有 327 人(17.6%)符合纳入标准。其中,173人(52.9%)为男性,年龄中位数(范围)为65.0(24.8-90.7)岁。平均(标清)随访间隔为 52.1(43.4)个月。327 名患者中,共有 18 人(5.5%)是新确诊的口咽癌症患者。最常见的诊断结果是鳞状细胞癌(9 例),其次是淋巴瘤(8 例)和肉瘤(1 例)。与检查结果正常的患者相比,偶然诊断出口咽癌的患者同侧SUVmax平均值(标度)(8.7 [3.7] vs 5.3 [1.9])和SUVmax比值(3.0 [1.6] vs 1.6 [0.6])较高。研究发现,SUVmax 比值和差异是口咽癌的良好鉴别指标,接收者操作特征曲线下的面积分别为 86.3%(95% CI,76.4-94.6)和 85.8%(95% CI,74.8-94.6)。与检查结果正常的患者相比,新诊断出口咽癌的患者更有可能出现相应的 CT 异常(18 例中的 6 例 [33%] 与 295 例中的 24 例 [8.1%])。与检查结果正常的患者相比,耳鼻喉科医护人员触诊口咽部时发现可疑病变的患者被诊断为口咽癌的几率明显更高(几率比,28.4;95% CI,6.6-145.8):在这项队列研究中,虽然口咽部 PET 意外非对称摄取很常见,但口咽癌的新诊断并不常见,这可能导致大量不必要的转诊和检查。使用 SUVmax 比值、SUVmax 差值和 CT 相关性可能会增加转诊的益处。口咽部可触及病变和不对称口咽部 PET 摄取的患者应进行确诊活检。
Cancer in Patients With Incidental Asymmetric Oropharynx Positron Emission Tomography Uptake.
Importance: Asymmetric oropharynx uptake on positron emission tomography (PET)/computed tomography (CT) is a common incidental finding and often prompts otolaryngology referral to rule out malignancy; however, the true risk of malignancy based on this finding is unknown.
Objective: To identify the incidence of oropharynx cancer in patients with incidental asymmetric oropharynx PET uptake.
Design, setting, and participants: In this retrospective cohort study, patients 18 years and older undergoing PET/CT scans at Mayo Clinic between January 2001 and December 2018 were included. Patients with a history or pretest suspicion of oropharynx cancer were excluded. Data were analyzed from March 2021 to December 2023.
Exposure: Blinded radiologic review of imaging studies, including measurement of maximum standardized uptake values (SUVmax) of the ipsilateral side of concern and contralateral side. Retrospective medical record review for associated clinical data.
Main outcomes and measures: The primary study outcome was the incidence of oropharynx cancer diagnosis in patients with asymmetric oropharynx PET uptake. The primary outcome was formulated before data collection.
Results: Of the 1854 patients identified with asymmetric oropharynx PET uptake, 327 (17.6%) met inclusion criteria. Of these, 173 (52.9%) were male, and the median (range) age was 65.0 (24.8-90.7) years. The mean (SD) follow-up interval was 52.1 (43.4) months. A total of 18 of 327 patients (5.5%) were newly diagnosed with oropharynx cancer. The most common diagnosis was squamous cell carcinoma (n = 9), followed by lymphoma (n = 8), and sarcoma (n = 1). Patients with an incidental diagnosis of oropharynx cancer had higher mean (SD) ipsilateral SUVmax (8.7 [3.7] vs 5.3 [1.9]) and SUVmax ratio (3.0 [1.6] vs 1.6 [0.6]) compared with patients with normal examination findings. SUVmax ratio and difference were found to be good discriminators of oropharynx cancer, with areas under the receiver operating characteristic curve of 86.3% (95% CI, 76.4-94.6) and 85.8% (95% CI, 74.8-94.6), respectively. Patients with a new diagnosis of oropharynx cancer were more likely to have a corresponding CT abnormality than those with normal examination findings (6 of 18 [33%] vs 24 of 295 [8.1%]). Patients with concerning lesions on oropharynx palpation by an otolaryngology health care professional were significantly more likely to be diagnosed with oropharynx cancer compared with patients with normal examination findings (odds ratio, 28.4; 95% CI, 6.6-145.8).
Conclusions and relevance: In this cohort study, while incidental asymmetric oropharynx PET uptake was common, a new diagnosis of oropharynx cancer was not and potentially results in a large volume of unnecessary referrals and work-up. Using SUVmax ratio, SUVmax difference, and CT correlation may increase the benefit of referral. Patients with a palpable oropharynx lesion and asymmetric oropharynx PET uptake should undergo confirmatory biopsy.
期刊介绍:
JAMA Otolaryngology–Head & Neck Surgery is a globally recognized and peer-reviewed medical journal dedicated to providing up-to-date information on diseases affecting the head and neck. It originated in 1925 as Archives of Otolaryngology and currently serves as the official publication for the American Head and Neck Society. As part of the prestigious JAMA Network, a collection of reputable general medical and specialty publications, it ensures the highest standards of research and expertise. Physicians and scientists worldwide rely on JAMA Otolaryngology–Head & Neck Surgery for invaluable insights in this specialized field.